Neonatal Respiratory Distress

Content: 
Contributors, Page ii
Front Matter, Page iii
Copyright, Page iv
Dedication, Page v
Contributors, Pages xiii-xiv
Foreword, Pages xv-xvi, Mary Ellen Avery
Preface, Pages xvii-xix, Philip M. Farrell
Terminology, Pages xxi-xxii
Contents of Volume I, Pages xxiii-xxv
Introduction to Clinical Aspects of Hyaline Membrane Disease, Page 1
1 - Historical Perspective: Past and Present Approaches to Therapy in Hyaline Membrane Disease, Pages 3-8, NICHOLAS M. NELSON
2 - Clinical Relevance of Pulmonary Surfactant, Pages 9-21, ROBERT V. KOTAS
3 - Overview of Hyaline Membrane Disease, Pages 23-46, PHILIP M. FARRELL
4 - Radiology of Hyaline Membrane Disease, Transient Tachypnea of the Newborn, and Bronchopulmonary Dysplasia, Pages 47-89, DAVID K. EDWARDS
5 - Pulmonary Function Abnormalities in Hyaline Membrane Disease and Bronchopulmonary Dysplasia, Pages 91-105, THOMAS H. SHAFFER, WILLIAM W. FOX
6 - Therapy of Hyaline Membrane Disease, Pages 107-133, GARY R. GUTCHER, ROBERT H. PERELMAN
7 - Long-Term Consequences of Hyaline Membrane Disease, Pages 135-152, DAVID N. SHEFTEL, ROBERT H. PERELMAN, PHILIP M. FARRELL
Introduction to Prevention of Hyaline Membrane Disease, Page 153
8 - Introduction to the Preventative Approach in Perinatal Care, Pages 155-158, PHILIP M. FARRELL
9 - Amniocentesis, Pages 159-166, LUIS B. CURET
10 - Prenatal Assessment of Fetal Lung Maturation: A Critical Review of Amniotic Fluid Phospholipid Tests, Pages 167-203, FRANCIS H.C. TSAO, RICHARD D. ZACHMAN
11 - Hormonal Aspects of Fetal Lung Development, Pages 205-253, PHILIP L. BALLARD
12 - The New Zealand Study of Antepartum Glucocorticoid Treatment, Pages 255-265, R.N. HOWIE, G.C. LIGGINS
13 - Design and Organization of a Multicenter Clinical Trial for the Study of Corticosteroid Effects on Human Lung Development, Pages 267-273, BITTEN STRIPP, PHILIP M. FARRELL
14 - The NIH Multicenter Study and Miscellaneous Clinical Trials of Antenatal Corticosteroid Administration, Pages 275-296, RICHARD D. ZACHMAN
15 - Current Recommendations for Use of Prenatal Corticosteroids Based on Assessment of the Risk-Benefit Relationship, Pages 297-300, RICHARD D. ZACHMAN, PHILIP M. FARRELL
Index, Pages 301-307